Dipeptidyl peptidase IV (DPP-IV) inhibitory peptides have emerged as promising functional ingredients for managing type 2 diabetes due to their ability to enhance insulin secretion and improve glycemic control. Here, INS is linked to type 2 diabetes mellitus.